• Inoviq surged more than 20% after reporting positive results on ovarian cancer study
  • Doctor Care Anywhere rose 30% after getting a loan from strategic partner
  • CSL has a new CEO


Inoviq (ASX:IIQ) has surged over 20% after reporting positive results from its Ovarian Cancer 97 study (OC97), confirming that EXO-NET is fit-for-purpose in ovarian cancer EV (extracellular vesicle) biomarkers.

The results also established the use of EXO-NET in generating multivariate index assay (MIA), with 92% accuracy for the detection of early-stage ovarian cancer.

Inoviq had collected data from 97 plasma samples (ovarian cancer, benign and healthy controls).

Through these data, the company identified highly significant differences between the EV biomarker content of ovarian cancer and control samples.

Of the EV biomarkers identified, 27 were highly informative (p<0.0001) of early-stage (stage I and II) ovarian cancer.

The study was completed by the Centre for Clinical Research at the University of Queensland (UQ).

“The OC97 study is the first milestone achieved in the collaboration with The University of Queensland to develop a world-first EV ovarian cancer screening test,” said Inoviq CEO, Dr Leearne Hinch.

The next step will be an analytical validation study to establish equivalence of the EV-based ovarian cancer test in plasma, compared to serum from the same cohort of patients.


Doctor Care Anywhere gets £10m loan

Doctor Care Anywhere (ASX:DOC) also surged almost 30% this morning after announcing a four-year, £10,000,000 secured loan agreement with AXA PPP Healthcare Group.

AXA is Doctor Care Anywhere’s major partner and its primary source of revenue, and has provided DCA with strong support over time.

“Today’s announcement is further evidence of AXA’s belief in the Doctor Care Anywhere service as an important benefit to its members,” said DOC chairman, Richard Dammery.

“The agreements announced today obviously increase DCA’s dependence on AXA, and enhance AXA’s rights in relation to the company, but they also ensure that the company can continue to develop innovative healthcare pathways into 2023 and beyond.”

DOC says the loan will be used for general working capital purposes in accordance with the terms.

CSL has a new CEO

Giant CSL (ASX:CSL) has appointed Dr Paul McKenzie as its new CEO commencing from 6 March 2023.

He is the current COO, and will succeed Paul Perreault, who has resigned after serving 10 years in the role and more than 25 years with the company.

CSL says that Dr McKenzie has more than 30 years of leadership experience in the global biotechnology industry, including managing complex organisations through compelling growth and transformation.

Since joining CSL as COO in 2019, Dr McKenzie has been accountable for optimising CSL’s operations as well as growing the CSL Seqirus, CSL Plasma, and CSL Vifor businesses.

Dr McKenzie will also join the board of directors as an executive director effective immediately.

The CSL share price fell 0.40% today.


Share prices today: